Delavirdine: Difference between revisions
Ahmed Zaghw (talk | contribs) |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
'''Delavirdine''' ('''DLV''') (brand name '''Rescriptor''') is a non-nucleoside [[reverse transcriptase inhibitor]] (NNRTI) marketed by [[ViiV Healthcare]]. It is used as part of highly active antiretroviral therapy (HAART) for the treatment of [[human immunodeficiency virus]] (HIV) type 1. It is presented as the mesylate. The recommended dosage is 400 mg, three times a day. | '''Delavirdine''' ('''DLV''') (brand name '''Rescriptor''') is a non-[[nucleoside]] [[reverse transcriptase inhibitor]] ([[NNRTI]]) marketed by [[ViiV Healthcare]]. It is used as part of highly active antiretroviral therapy (HAART) for the treatment of [[human immunodeficiency virus]] (HIV) type 1. It is presented as the mesylate. The recommended dosage is 400 mg, three times a day. | ||
Although delavirdine was approved by the U.S. [[Food and Drug Administration]] in 1997, its efficacy is lower than other NNRTIs, especially [[efavirenz]], and it also has an inconvenient schedule. These factors have led the U.S. DHHS not to recommend its use as part of initial therapy.<ref name="dhhs">DHHS panel. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (May 4, 2006). (Available for download from [http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID=7&ClassID=1 AIDSInfo])</ref> | Although delavirdine was approved by the U.S. [[Food and Drug Administration]] in 1997, its efficacy is lower than other NNRTIs, especially [[efavirenz]], and it also has an inconvenient schedule. These factors have led the U.S. DHHS not to recommend its use as part of initial therapy.<ref name="dhhs">DHHS panel. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (May 4, 2006). (Available for download from [http://www.aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&Search=Off&GuidelineID=7&ClassID=1 AIDSInfo])</ref> | ||
| Line 10: | Line 10: | ||
==Category== | ==Category== | ||
Antiretroviral | |||
Antiretroviral | |||
==US Brand Names== | ==US Brand Names== | ||
RESCRIPTOR<sup>®</sup> | |||
==FDA Package Insert== | ==FDA Package Insert== | ||
| Line 29: | Line 32: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
Delavirdine blocks DNA polymerase activity by binding directly to reverse transcriptase. | |||
==References== | ==References== | ||
Revision as of 03:41, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Overview
Delavirdine (DLV) (brand name Rescriptor) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) marketed by ViiV Healthcare. It is used as part of highly active antiretroviral therapy (HAART) for the treatment of human immunodeficiency virus (HIV) type 1. It is presented as the mesylate. The recommended dosage is 400 mg, three times a day.
Although delavirdine was approved by the U.S. Food and Drug Administration in 1997, its efficacy is lower than other NNRTIs, especially efavirenz, and it also has an inconvenient schedule. These factors have led the U.S. DHHS not to recommend its use as part of initial therapy.[1] The risk of cross-resistance across the NNRTI class, as well as its complex set of drug interactions, make the place of delavirdine in second-line and salvage therapy unclear, and it is currently rarely used.
Category
Antiretroviral
US Brand Names
RESCRIPTOR®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
Delavirdine blocks DNA polymerase activity by binding directly to reverse transcriptase.